Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

Andrew Davies; Francesco Merli; Biljana Mihaljević; Santiago Mercadal; Noppadol Siritanaratkul; Philippe Solal-Céligny; Axel Boehnke; Claude Berge; Magali Genevray; Artem Zharkov; Mark Dixon; Michael Brewster; Martin Barrett; David MacDonald

doi:10.1016/s2352-3026(17)30078-9

Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial

The Lancet Haematology ◽

10.1016/s2352-3026(17)30078-9 ◽

2017 ◽

Vol 4 (6) ◽

pp. e272-e282 ◽

Cited By ~ 44

Author(s):

Andrew Davies ◽

Francesco Merli ◽

Biljana Mihaljević ◽

Santiago Mercadal ◽

Noppadol Siritanaratkul ◽

...

Keyword(s):

Follicular Lymphoma ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

A multicenter, open-label, phase 3 trial to compare the efficacy and safety of lenvatinib (E7080) versus sorafenib in first-line treatment of subjects with unresectable hepatocellular carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.tps4153 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. TPS4153-TPS4153 ◽

Cited By ~ 8

Author(s):

Richard S. Finn ◽

Ann-Lii Cheng ◽

Kenji Ikeda ◽

Masatoshi Kudo ◽

Toshiyuki Tamai ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Unresectable Hepatocellular Carcinoma ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma in a phase 3, randomized, open-label, multicenter study - Trial in progress

Annals of Oncology ◽

10.1093/annonc/mdy151.181 ◽

2018 ◽

Vol 29 ◽

pp. v51

Author(s):

S. Qin ◽

R. Finn ◽

M. Kudo ◽

T. Meyer ◽

A. Vogel ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Multicenter Study ◽

Study Trial ◽

Advanced Hepatocellular Carcinoma ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Download Full-text

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70330-4 ◽

2014 ◽

Vol 15 (10) ◽

pp. 1065-1075 ◽

Cited By ~ 881

Author(s):

Volker Heinemann ◽

Ludwig Fischer von Weikersthal ◽

Thomas Decker ◽

Alexander Kiani ◽

Ursula Vehling-Kaiser ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

A phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of tislelizumab, an anti-PD-1 antibody, versus sorafenib as first-line treatment in patients with advanced hepatocellular carcinoma.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.tps3110 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. TPS3110-TPS3110 ◽

Cited By ~ 8

Author(s):

Shukui Qin ◽

Richard S. Finn ◽

Masatoshi Kudo ◽

Tim Meyer ◽

Arndt Vogel ◽

...

Keyword(s):

Hepatocellular Carcinoma ◽

Multicenter Study ◽

Advanced Hepatocellular Carcinoma ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Download Full-text

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30436-8 ◽

2020 ◽

Vol 21 (12) ◽

pp. 1563-1573 ◽

Cited By ~ 3

Author(s):

Thomas Powles ◽

Elizabeth R Plimack ◽

Denis Soulières ◽

Tom Waddell ◽

Viktor Stus ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Cell Carcinoma ◽

Renal Cell ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

The Lancet ◽

10.1016/s0140-6736(19)32222-6 ◽

2019 ◽

Vol 394 (10212) ◽

pp. 1929-1939 ◽

Cited By ~ 172

Author(s):

Luis Paz-Ares ◽

Mikhail Dvorkin ◽

Yuanbin Chen ◽

Niels Reinmuth ◽

Katsuyuki Hotta ◽

...

Keyword(s):

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Extensive Stage ◽

Randomised Controlled ◽

First Line Treatment

Download Full-text

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study

The Lancet Oncology ◽

10.1016/s1470-2045(15)00122-9 ◽

2015 ◽

Vol 16 (13) ◽

pp. 1306-1315 ◽

Cited By ~ 398

Author(s):

Chiara Cremolini ◽

Fotios Loupakis ◽

Carlotta Antoniotti ◽

Cristiana Lupi ◽

Elisa Sensi ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Molecular Subgroup ◽

Subgroup Analyses ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Capecitabine and bevacizumab with or without vinorelbine in first-line treatment of HER2/neu-negative metastatic or locally advanced breast cancer: final efficacy and safety data of the randomised, open-label superiority phase 3 CARIN trial

Breast Cancer Research and Treatment ◽

10.1007/s10549-016-3727-x ◽

2016 ◽

Vol 156 (1) ◽

pp. 97-107 ◽

Cited By ~ 9

Author(s):

A. Welt ◽

N. Marschner ◽

C. Lerchenmueller ◽

T. Decker ◽

C.-C. Steffens ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced Breast Cancer ◽

Locally Advanced ◽

Safety Data ◽

Line Treatment ◽

Efficacy And Safety ◽

First Line ◽

Open Label ◽

Phase 3 ◽

First Line Treatment

Download Full-text

Gemcitabine or Abraxane Combined with cisPlatin (GAP) as First-Line Treatment in Patients with Metastatic Triple-Negative Breast Cancer: A Multicenter, Randomized, Open-Label, Phase 3 Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3715466 ◽

2020 ◽

Author(s):

Biyun Wang ◽

Tao Sun ◽

Yannan Zhao ◽

Shusen Wang ◽

Jian Zhang ◽

...

Keyword(s):

Breast Cancer ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

First Line Treatment

Download Full-text

Faculty Opinions recommendation of FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725768305.793550889 ◽

2018 ◽

Author(s):

Sebastian Stintzing

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Line Treatment ◽

First Line ◽

Open Label ◽

Phase 3 ◽

Molecular Subgroup ◽

Subgroup Analyses ◽

Open Label Phase ◽

First Line Treatment

Download Full-text